We’re excited to announce that we will be participating in the 7th T-Cell Engager Therapeutics Summit. As the event focused exclusively on advancing T-cell engagers from discovery to clinic, this summit is the perfect platform to connect with industry leaders and showcase our innovative antibody discovery platforms and preclinical solutions. Come visit our booth to grab brochures and flyers, meet our team, and learn how Biocytogen is accelerating the development of next-generation immunotherapies. We look forward to connecting with you and exploring new opportunities together!
What is 7th T-Cell Engager Therapeutics Summit?
The 7th T-Cell Engager Therapeutics Summit is a leading industry event focused exclusively on developing and translating T-cell engagers (TCEs) and immune cell engager therapies. It brings together biotech, pharma, and academic experts to address key challenges such as improving efficacy in solid tumors, reducing toxicity, and identifying novel targets. The summit highlights the latest innovations, clinical strategies, and business developments shaping the future of immuno-oncology and beyond, including emerging applications in autoimmune diseases.
Event Overview
Date: June 24, 2025 - June 26, 2025
Venue: Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA
Event Schedule
The 7th T-Cell Engager Therapeutics Summit invited immuno-oncology professionals to speak. For more details on the event, please download the summit brochures from the Event Guide.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you in the 7th T-Cell Engager Therapeutics Summit at Boston, MA!
